Join the Oncology Brothers, Drs Rahul and Rohit Gosain, as they host an insightful discussion with Dr Lorenza Rimassa and Prof. Arndt Vogel. In the second of a 4-part podcast series, this episode dives into 2nd line treatment selection in advanced HCC and the key considerations for deciding when to switch therapies. Topics include: 2nd line options for advanced HCC after 1st line TKIs and IO-based therapies Sequencing strategies and clinical practice approaches Key data supporting 2nd line decisions Factors to consider when transitioning to 2nd line therapy Key clinical takeaways: Prospective Phase 3 data on 2nd line options in advanced HCC, particularly after immunotherapy, is limited, highlighting the need for further evidence to guide optimal treatment decisions When switching to 2nd line therapy, it is essential to evaluate all the available treatment options to ensure the optimal choice for each patient, considering efficacy, tolerability, liver function, and quality of life. Switching to 2nd line therapy should be considered in cases of clear disease progression, such as the appearance of new lesions outside the liver. Best supportive care should also be considered Managing side effects of 2nd line treatments (e.g. hypertension, skin toxicity, proteinuria) is critical for maintaining quality of life and providing optimal disease management Effective management requires a multidisciplinary team effort, including oncologists, hepatologists, interventional radiologists, and other specialists to optimise outcomes and proactively manage symptoms like hepatic decompensation Prefer to watch the experts in conversation? Go to the video on our website: https://cor2ed.com/hcc-connect/programmes/advanced-hcc-treatment-selection/ Follow us on social media: LinkedIn: https://www.linkedin.com/company/hcc-connect X: https://x.com/hccconnectinfo This content is intended for healthcare professionals only. The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer. This podcast is developed by cor2ed.com Published December 2024 Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related